We now have two vaccinations to protect against herpes zoster — a live-attenuated vaccine (Zostavax) and the new recombinant subunit vaccine (Shingrix). While the live-attenuated vaccine has been available for more than a decade and a CDC-recommended vaccine in older adults, only one in three eligible patients have received it. Based on the results of two recently published studies, the new recombinant subunit vaccine appears to provide substantially improved efficacy and duration.
Guest Author: Katherine Montag Schafer, PharmD, BCACP
Music by Good Talk